Biotechnology - Neurological

Filter

Current filters:

Neurological

Popular Filters

1 to 25 of 189 results

C4X Discovery enters into new research agreement with Evotec AG for treating addiction

C4X Discovery enters into new research agreement with Evotec AG for treating addiction

19-01-2015

UK-based C4X Discovery Holdings has entered into a research agreement with drug discovery alliance Evotec.

BiotechnologyC4X DiscoveryEvotec AGLicensingNeurologicalUK

Novogen identifies family of compounds to promote brain stem cell growth

Novogen identifies family of compounds to promote brain stem cell growth

16-01-2015

Australian biotech firm Novogen has announced an important discovery in its regenerative medicine program…

BiotechnologyNeurologicalNovogenResearch

Treeway collaborates with uniQure on gene therapy for ALS

15-01-2015

Netherlands-based biotech firm Treeway has entered into a collaboration with Dutch gene therapy company…

BiotechnologyLicensingNeurologicalResearchTreewayuniQure

Biogen Idec to acquire Convergence Pharma in potential $675 million deal

12-01-2015

US biotech major Biogen Idec has agreed to acquire independent UK-based Convergence Pharmaceuticals,…

Biogen IdecBiotechnologyCNV-1014802Convergence PharmaceuticalsMergers & AcquisitionsNeurologicalPainUnited Kingdom

AC Immune out-licenses anti-Tau vaccine to Janssen in up to $509 million deal

12-01-2015

Switzerland’s biopharma company AC Immune has entered into a worldwide exclusive license agreement…

AC ImmuneBiotechnologyGlobalJanssen Research & DevelopmentJohnson & JohnsonLicensingNeurological

Egalet buys in two innovative approved pain products, Oxaydo and Sprix

09-01-2015

US biotech firm Egalet Corp has in-licensing two innovative approved pain products transforming Egalet…

Acura PharmaceuticalsBiotechnologyDaiichi SankyoEgalet CorpGlobalLicensingLuitpold PharmaNeurologicalOxaydoSPRIX

Alkermes rises on positive ALKS 5461 results

07-01-2015

Shares of Ireland-headquartered biotech firm Alkermes closed up 2.6% to $60.93, having risen as much…

AlkermesALKS 5461BiotechnologyNeurologicalResearch

23andMe and Genentech in deal to analyze genomic data for Parkinson's disease

06-01-2015

23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche,…

23andMeBiotechnologyGenentechNeurologicalResearchRoche

Roivant acquires GSK's Alzheimer's drug

Roivant acquires GSK's Alzheimer's drug

29-12-2014

Bermuda-based biotech firm Roivant Neurosciences, wholly-owned subsidiary of Roivant Sciences, has entered…

BiotechnologyGlaxoSmithKlineLicensingNeurologicalRoivant

RXi and Hapten enter into licensing agreement for Samcyprone

RXi and Hapten enter into licensing agreement for Samcyprone

19-12-2014

RNA technology specialist RXi Pharmaceuticals Corp has entered into a global licensing agreement with…

BiotechnologyDermatologicalsLicensingNeurologicalRXi Pharmaceuticals

Novartis venture fund leads $34 million financing for Annexon Bioscience

Novartis venture fund leads $34 million financing for Annexon Bioscience

17-12-2014

USA-based Annexon Bioscience says it has closed a $34 million Series A-1 to support the development of…

Annexon BioscienceANX005BiotechnologyFinancialNeurologicalNovartis

Credit Suisse sees PTC Therapeutics as a top stock pick

05-12-2014

Credit Suisse has released a biotech research report from analysts Jason Kantor and Jeremiah Shepard…

BiotechnologyFinancialNeurologicalPTC TherapeuticsRare diseasesRegulationTranslarna

Forward Pharma sues Biogen Idec over Tecfidera sales in Germany

18-11-2014

Danish biopharmaceutical company Forward Pharma has filed a law suit against US biotech major Biogen…

Biogen IdecBiotechnologyForward PharmaGermanyLegalMarkets & MarketingNeurologicalTecfidera

FDA at last approves Genzyme’s Lemtrada

FDA at last approves Genzyme’s Lemtrada

15-11-2014

The US Food and Drug Administration on Friday approved French pharma major Sanofi subsidiary Genzyme’s…

BayerBiotechnologyGenzymeLemtradaNeurologicalRegulationSanofiUSA

Actinogen acquires Edinburgh BioQuarter spin-out Corticrine

Actinogen acquires Edinburgh BioQuarter spin-out Corticrine

31-10-2014

Australian biotech firm Actinogen has acquired Edinburgh BioQuarter spin-out, Corticrine.

ActinogenBiotechnologyCorticrineEdinburgh BioQuarterMergers & AcquisitionsNeurological

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

28-10-2014

US drugmaker Alexza Pharmaceuticals and privately-held Spanish firm Grupo Ferrer Internacional have amended…

AdasuveAlexza PharmaceuticalBiotechnologyFerrer InternacionalFinancialLicensingNeurologicalUSA

Biogen Idec third-qtr net rockets 76% but shares slump

Biogen Idec third-qtr net rockets 76% but shares slump

23-10-2014

US biotech firm Biogen Idec saw its share price plunge 7% to $303.51, after its posted third-quarter…

Biogen IdecBiotechnologyFinancialNeurologicalTecfideraUSA

Astellas and CoMentis to end Alzheimer’s collaboration

20-10-2014

Japanese drug major Astellas Pharma and US biotech firm CoMentis have said they will end their worldwide…

Astellas PharmaBiotechnologyCoMentisLicensingNeurologicalResearch

After nine years, AstraZeneca finally ditches Targacept

12-10-2014

On October 8, 2014, Anglo-Swedish pharma major AstraZeneca finally terminated its collaborative research…

AstraZenecaBiotechnologyGenito-urinaryLicensingNeurologicalTargacept

US FDA grants Fast Track status to BrainStorm Cell Therapeutics for ALS treatment NurOwn

US FDA grants Fast Track status to BrainStorm Cell Therapeutics for ALS treatment NurOwn

07-10-2014

The US Food and Drug Administration has designated a product from stem cell treatment developer BrainStorm…

BiotechnologyBrainStorm Cell TherapeuticsNeurologicalNurOwnRegulationUSA

Acorda Therapeutics to acquire Civitas for $525 million

24-09-2014

US biotech firm Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a…

Acorda TherapeuticsBiotechnologyCivitas TherapeuticsCVT-301Mergers & AcquisitionsNeurological

Biotie receives final European milestone from Lundbeck on Selincro French launch

Biotie receives final European milestone from Lundbeck on Selincro French launch

19-09-2014

Danish CNS drug specialist Lundbeck has brought Selincro (nalmefene) on the market in France. Selincro,…

BiotechnologyBiotie TherapiesFinlandFranceLicensingLundbeckNeurologicalSelincro

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

12-09-2014

US biotech firm Biogen Idec has reported data confirming its Plegridy gives provides treatment effects…

Biogen IdecBiotechnologyNeurologicalPlegridyResearchUSA

Strong and sustained efficacy reported for Tecfidera over five years

Strong and sustained efficacy reported for Tecfidera over five years

12-09-2014

Results from a five-year study with US biotech firm Biogen Idec’s Tecfidera show strong and sustained…

Biogen IdecBiotechnologyNeurologicalResearchTecfideraUSA

1 to 25 of 189 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top